Cargando…
Complement control for COVID-19
Excessive complement activation contributes to lung disease and adverse patient outcomes in COVID-19 (see the related research articles by Yan et al. and Ma et al.).
Autor principal: | Bosmann, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432947/ https://www.ncbi.nlm.nih.gov/pubmed/34035117 http://dx.doi.org/10.1126/sciimmunol.abj1014 |
Ejemplares similares
-
Complement Activation during Critical Illness: Current Findings and
an Outlook in the Era of COVID-19
por: Bosmann, Markus
Publicado: (2020) -
Study on e-commerce logistics cost control methods in the context of COVID-19 prevention and control
por: Ding, Qi, et al.
Publicado: (2021) -
IoT-based analysis for controlling & spreading prediction of COVID-19 in Saudi Arabia
por: Sharma, Sunil Kumar, et al.
Publicado: (2021) -
Care for the chronically ill in Germany – The challenges during the COVID-19 pandemic
por: Scheidt-Nave, Christa, et al.
Publicado: (2020) -
Optimization model design of cross-border e-commerce transportation path under the background of prevention and control of COVID-19 pneumonia
por: Abudureheman, Abuduaini, et al.
Publicado: (2021)